India denies price hikes to Sanofi, Novartis, Allergan; Lundbeck launches Selincro in U.K.;

@FiercePharma: WSJ: J&J's multibillion-$$ Risperdal settlement snags on breast side effects. $JNJ worried a/b civil suits. Article | Follow @FiercePharma

 @EricPFierce: Pharma M&A way up in Q1 2013 compared to a year ago. Value up more than 500%. Feature | Follow @EricPFierce

> Lundbeck has launched Selincro, its drug for alcohol dependence, in the U.K. Story

> India's National Pharmaceutical Pricing Authority (NPPA) has denied price boosts to Sanofi ($SNY), Novartis ($NVS), and Allergan ($AGN) for some of their imported drugs. Story

> Cipla and three other Indian drug companies are being investigated for their parts in an alleged deal that gave them preferential treatment for drug contracts. Story

> Pain Therapeutics, said Pfizer ($PFE), is unsure if it wants to go forward with regulatory approval for the painkiller Remoxy. Report

> Ralph Neas, CEO of the Generic Pharmaceutical Association (GPhA), used a letter in The New York Times to take a swipe at state laws restricting biosimilars. Letter

Medical Device News

@FierceMedDev: Boston Scientific: Watchman beats warfarin in follow-up. Article | Follow @FierceMedDev

@MarkHFierce: Nanostim's leadless pacer has had some success in early human trials. Future buyer St. Jude Medical must be pleased. Story | Follow @MarkHFierce

 @DamianFierce: St. Jude: Independent analysis says Durata leads are safe, reliable. Report | Follow @DamianFierce

> CareFusion's revenue slips 2%. Item

> U.K. pair challenges earlier finding that substandard PIP breast implants were safe. Report

> Quest settles New York case over illegal hiring practices. Story

Biotech News

@FierceBiotech: Special report: Which Big Biotechs are hitting the gas pedal on R&D spending? Feature | Follow @FierceBiotech

@JohnCFierce: Looks like Takeda management maybe in for more changes.The numbers are awful. Report | Follow @JohnCFierce

@RyanMFierce: My story on how industry legend Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups. Article | Follow @RyanMFierce

> Eli Lilly jettisons cancer contender after another Phase III failure. Story

> Biotech VC firm Frazier Healthcare closes in on $300M fund. More

> Deborah Dunsire exits as Takeda cuts CEO role in Millennium shakeup. News

And Finally... Federal authorities in Puerto Rico have arrested a Pfizer executive that they say sent sexually explicit photos to a 16-year-old boy. Story

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.